US2008119410A1PendingUtilityA1

Modulation of Pericyte Proliferation

Assignee: XOMA TECHNOLOGY LTDPriority: Dec 1, 2000Filed: Oct 8, 2007Published: May 22, 2008
Est. expiryDec 1, 2020(expired)· nominal 20-yr term from priority
A61P 37/00A61P 9/12A61P 3/10A61P 9/00A61P 9/10A61P 43/00A61P 27/02A61P 25/00A61P 25/28A61P 17/00G01N 33/5008G01N 33/5044A61P 19/08A61P 17/02A61P 21/00A61P 15/00A61P 11/00G01N 33/5011A61K 38/1751G01N 33/5017A61P 15/08G01N 33/5041
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and materials for modulating pericyte and epithelial cell proliferation relating to BPI protein products or inhibitors thereof are provided.

Claims

exact text as granted — not AI-modified
1 . A method of enhancing pericyte cell proliferation comprising administering to a subject in need thereof an amount of a BPI protein product effective to enhance proliferation of pericyte cells. 
     
     
         2 - 4 . (canceled) 
     
     
         5 . The method of  claim 1  wherein the subject is suffering from age related macular degeneration (ARMD). 
     
     
         6 - 19 . (canceled) 
     
     
         20 . The method of  claim 1  wherein the BPI protein product is an amino-terminal fragment of BPI protein having a molecular weight of about 20 kD to 25 kD, or a dimeric form thereof. 
     
     
         21 . The method of  claim 1  wherein the BPI protein product is a BPI-derived peptide. 
     
     
         22 . The method of  claim 21  wherein the BPI-derived peptide is XMP.679. 
     
     
         23 - 34 . (canceled) 
     
     
         35 . A method of enhancing pericyte proliferation in a subject suffering from a pericyte degeneration disorder that is age related macular degeneration (ARMD), comprising administering to the subject an amount of a BPI protein product effective to enhance proliferation of pericytes. 
     
     
         36 - 39 . (canceled)

Join the waitlist — get patent alerts

Track US2008119410A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.